Atracurium

CHEMBL1360 Phase 4 Aprovado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
929.1 g/mol
LogP
7.9
Phase
4

A non-depolarizing neuromuscular blocking agent that competes with acetylcholine at the neuromuscular junction, causing temporary muscle paralysis to facilitate mechanical ventilation or surgical procedures. It breaks down spontaneously in the blood.

Peso Molecular

929,1000 g/mol

LogP

7,90

TPSA

126,00 Ų

Regra dos 5 de Lipinski

Reprovado

Áreas Terapêuticas

Mecanismo de Ação

Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.

Estrutura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

COc1ccc(CC2c3cc(OC)c(OC)cc3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCc3cc(OC)c(OC)cc3C2Cc2ccc(OC)c(OC)c2)cc1OC

InChI

InChI=1S/C53H72N2O12/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6/h14-17,30-35,42-43H,11-13,18-29H2,1-10H3/q+2

Molecular Formula

C53H72N2O12+2

HBD / HBA

- / 12

Ligações Rotacionáveis

26

Átomos Pesados

67

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

A non-depolarizing neuromuscular blocking agent that competes with acetylcholine at the neuromuscular junction, causing temporary muscle paralysis to facilitate mechanical ventilation or surgical procedures. It breaks down spontaneously in the blood.

Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.

Yes, Atracurium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1360. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 47319. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.